The Karnofsky performance score is now widely used by oncologists for patients with lung cancer but has been neglected by physicians dealing with non-small cell lung cancer, particularly in routine clinical practice as opposed to clinical trials.
Using the performance categories of "ambulatory" and "non-ambulatory" in patients with small cell and non-small cell lung cancer, Lagakos and colleagues found that these very simple criteria provided a more useful predictor of median survival than stage of disease or cell type. ' 
